Metastatic Prostate Cancer Prognosis Worksheet

About the Metastatic Prostate Cancer Prognosis Worksheet

Metastatic prostate cancer covers a broad range of disease states, from newly diagnosed hormone-sensitive disease to later castration-resistant disease after multiple lines of therapy. Prognosis varies widely with metastatic burden, tumor biology, performance status, laboratory profile, and response to treatment.

This page combines several commonly discussed prognostic features — ECOG status, PSA, Gleason or grade-group pattern, disease extent, and selected laboratory values — into a simplified worksheet. It uses familiar trial concepts such as CHAARTED disease volume to help organize those factors, but it does not reproduce a single validated survival model.

The output should therefore be read as broad prognosis context only. It is meant to help users summarize the case before an oncology discussion, not to replace specialist review, imaging, genomic workup, or formal treatment planning.

When This Page Helps

Metastatic prostate-cancer prognosis depends on disease burden, biology, performance status, treatment setting, and many factors this page cannot fully capture. This worksheet is most useful when it helps organize those visible factors before a specialist discussion.

How to Use the Inputs

1. Select the disease setting — newly diagnosed hormone-naïve, mCRPC pre-chemo, or post-docetaxel.
2. Enter the patient's age and select ECOG performance status.
3. Enter current PSA level and select Gleason score.
4. Choose the disease extent from the dropdown (lymph nodes, bone burden, visceral mets).
5. Optionally enter lab values (ALP, LDH, hemoglobin, albumin) for refined stratification.
6. Review composite risk group, estimated survival, and treatment considerations.

Example Calculation

Tips & Best Practices

• Always confirm castrate testosterone levels (< 50 ng/dL) before diagnosing castration resistance.
• Genomic testing (HRR genes) should be performed for all mCRPC patients — PARP inhibitors improve survival.
• Rising PSA alone without radiographic progression is not sufficient for treatment changes.
• Consider clinical trials for all mCRPC patients, especially at each line-of-therapy transition.
• PSMA PET has superior sensitivity for detecting metastases versus conventional imaging.
• Bone health (denosumab or zoledronic acid) should be initiated for skeletal event prevention.

What This Worksheet Summarizes

This page pulls together several prognostic features that commonly appear in metastatic prostate-cancer discussions: disease setting, ECOG status, PSA, grade group, metastatic burden, and selected laboratory abnormalities. It is meant to summarize those features in one place, not to replace formal prognostic models or multidisciplinary review.

Why Trial Criteria Still Matter

Trial frameworks such as CHAARTED and LATITUDE remain useful because they describe broad high-burden and lower-burden disease patterns that track with outcomes and treatment intensity. They are helpful anchors for interpretation, but they are not the whole prognosis story by themselves.

Limits

Modern prognosis depends on more than the variables on this page. Genomic findings, imaging response, visceral disease pattern, treatment history, symptoms, castration status, and access to newer therapies all matter. That is why the output is presented as worksheet context rather than as a definitive survival prediction.

Frequently Asked Questions

• What is the difference between mCSPC and mCRPC?

  Metastatic castration-sensitive prostate cancer (mCSPC) refers to disease that still responds to androgen deprivation therapy (ADT). Metastatic castration-resistant prostate cancer (mCRPC) is disease that progresses despite castrate testosterone levels (< 50 ng/dL). The transition to CRPC represents a critical inflection point in the disease trajectory, with shorter expected survival and different treatment options.

• What is CHAARTED high-volume disease?

  The CHAARTED trial defined high-volume disease as having ≥ 4 bone metastases with at least 1 beyond the axial skeleton (spine/pelvis), OR having visceral metastases (liver, lung, brain, etc.). High-volume disease has significantly worse prognosis and benefits most from upfront combination therapy (ADT + docetaxel ± novel hormone agent) compared to ADT alone.

• How does Gleason score affect prognosis?

  Higher Gleason scores (grade groups 4-5, Gleason 8-10) indicate more aggressive tumor biology with poorer differentiation and higher proliferation rates. These cancers are more likely to develop castration resistance quickly and metastasize to visceral organs. Gleason 9-10 disease carries the worst prognosis and often requires the most aggressive combination treatment.

• Should all patients get triplet therapy?

  Triplet therapy (ADT + docetaxel + novel hormone agent like abiraterone) has shown benefit particularly in high-volume/high-risk mCSPC (PEACE-1, ARASENS). However, it carries increased toxicity. Low-volume disease may be adequately treated with ADT + a novel hormone agent alone. Treatment selection should balance expected benefit against toxicity, considering patient fitness, comorbidities, and preferences.

• What role does genomic testing play?

  Homologous recombination repair (HRR) gene testing (BRCA1, BRCA2, ATM, PALB2, etc.) is now standard in mCRPC. BRCA1/2 mutations predict response to PARP inhibitors (olaparib, rucaparib). Microsatellite instability (MSI-H) may predict response to pembrolizumab. Tumor mutational burden and other biomarkers are being studied. These do not replace clinical prognostic factors but add precision to treatment selection.

• Why is alkaline phosphatase important?

  ALP reflects osteoblastic bone activity and is elevated when prostate cancer metastasizes to bone. Higher ALP levels correlate with greater bone tumor burden and shorter survival. ALP > 200 U/L is an independent adverse prognostic factor across multiple models (Halabi, Armstrong). It can also serve as a treatment response marker — declining ALP often indicates responding disease.